Innoviva Specialty Therapeutics, Inc.’s Post

We are incredibly honored to have been nominated for the #PrixGalienUSA2024 “Best Biotechnology Product Award” for XACDURO®, our pathogen-targeted antibiotic against hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in adults caused by Acinetobacter baumannii. Thank you to the @Galien Foundation and the award committee for recognizing our innovation and efforts to bring XACDURO to patients. #lifesciences #healthcareinnovation #biotech

  • No alternative text description for this image
Gerard Fernandes

Agile Leader | Collaborate to Innovate | Value Creator | Change Agent | Culture Developer | BioPharma | Rare Disease | Medical Device

3mo

Congratulations on this incredible achievement Stephen.

Like
Reply
Sal Saraceno

Managing Director, Healthcare Investment Banking at Capital One

2mo

Terrific, congratulations, Stephen

Like
Reply
Orli Shvartzman, MBA

Director, Corporate Financial Planning and Analysis at Balt

2mo

Congratulations!

Like
Reply
Orli Shvartzman, MBA

Director, Corporate Financial Planning and Analysis at Balt

3mo

Congrats!

Like
Reply
Ed Cronin

Executive Vice President at Aon

3mo

Congrats!

Like
Reply
Demetrios Braddock

Associate Professor, Yale University & Scientific Founder, Inozyme

3mo

Congrats Steve!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics